Bio-Rad Laboratories (BIO) 145.59 $BIO Bio-Rad Unveils

New Post Public Reply Private Reply Replies (0) Message Board

Jun 13, 2016 at 3:16 PM

Bio-Rad Laboratories (BIO) 145.59 $BIO

Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Bio-Rad Laboratories, Inc.
ACCESSWIRE - Mon May 16, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Levi & Korsinsky announces it has commenced an investigation of Bio-Rad Laboratories, Inc. (NYSE: BIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/bio-rad-laboratories or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
BIO: 145.59 (-0.99)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Mon May 16, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.59 (-0.99)

Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 145.59 (-0.99), ILMN: 140.47 (-1.15), BIO.B: 145.73 (-3.31)

Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 10.15 (-0.34), BIO: 145.59 (-0.99), ILMN: 140.47 (-1.15), EXAC: 25.58 (+0.16)

Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 151.31 (-1.06), BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
BusinessWire - Mon Jan 11, 1:31PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
BIO: 145.59 (-0.99), ILMN: 140.47 (-1.15)

Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

FDA Okays Bio-Rad D-100 for HbA1c (Diabetes) Testing
Zacks Equity Research - Zacks Investment Research - Mon Dec 21, 1:25PM CST
Bio-Rad's (BIO) D-100 System delivers rapid high-quality HbA1c testing, without sacrificing the ability to detect hemoglobin variants that can interfere with the interpretation of test results.
CAPR: 3.50 (+0.29), ICUI: 107.32 (-0.01), INSY: 13.78 (-0.21), BIO: 145.59 (-0.99)

10X Genomics Founders Prevail in Dispute with Bio-Rad
BusinessWire - Mon Dec 21, 6:00AM CST
10X Genomics, Inc., today announced that its founders and executive officers, Drs. Serge Saxonov, Benjamin Hindson and Kevin Ness, have unequivocally prevailed in an arbitrated dispute brought against them by Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.59 (-0.99)

Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
Marketwired - Wed Dec 16, 5:19PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that its D-100(TM) System for A1c testing has obtained clearance from the U.S. Food and Drug Administration to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
BIO: 145.59 (-0.99), BIO.B: 145.73 (-3.31)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...